11,597 results match your criteria Annals Of Oncology[Journal]


ER+/HER2+ breast cancer: are we really de-escalating?

Ann Oncol 2019 Apr 16. Epub 2019 Apr 16.

Medicine, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz130DOI Listing
April 2019
1 Read

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

Ann Oncol 2019 Apr 13. Epub 2019 Apr 13.

Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.

Background: In the ongoing phase 1 PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz131DOI Listing

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.

Ann Oncol 2019 Apr 12. Epub 2019 Apr 12.

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background: Immune checkpoint blockade with PD-1/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However, emerging evidence show that PD-1/PD-L1 blockade can lead to hyperprogressive disease (HPD), a flair-up of tumor growth linked to dismal prognosis. This study aimed to evaluate the incidence of HPD and identify the determinants associated with HPD in patients with NSCLC treated with PD-1/PD-L1 blockade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz123DOI Listing
April 2019
7.040 Impact Factor

Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection.

Ann Oncol 2019 Apr 12. Epub 2019 Apr 12.

Molecular Therapeutics Research Unit (UITM). Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
https://academic.oup.com/annonc/advance-article/doi/10.1093/
Publisher Site
http://dx.doi.org/10.1093/annonc/mdz129DOI Listing
April 2019
1 Read

RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor.

Ann Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Pharmacogenomics, Saint-Louis Hospital, Paris-Diderot University, Sorbonne Paris Cité, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz125DOI Listing

T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.

Ann Oncol 2019 Apr 2. Epub 2019 Apr 2.

University of Milano, Department of Hematology and Oncology, European Institute of Oncology, IRCCS, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz115DOI Listing

Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial.

Ann Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Radiology, Foundation IRCCS National Cancer Institute of Milan, Italy.

Background: The National Lung Screening Trial (NLST) showed that lung cancer (LC) screening by three annual rounds of low-dose computed tomography (LDCT) reduces lung cancer mortality. We evaluated the benefit of prolonged LDCT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years.

Design: The Multicentric Italian Lung Detection (MILD) trial prospectively randomized 4,099 participants, to a screening arm (n = 2,376), with further randomization to annual (n = 1190) or biennial (n = 1186) LDCT for a median period of six years, or control arm (n = 1,723) without intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz117DOI Listing

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Ann Oncol 2019 Mar 29. Epub 2019 Mar 29.

Gustave Roussy Cancer Campus (GRCC), Villejuif, France.

Background: Tumor-infiltrating lymphocytes (TILs) represent a prognostic factor for survival in primary breast cancers (BC). Nonetheless, neoepitope load and TILs cytolytic activity are modest in BC, compromising the efficacy of immune-activating antibodies, which do not yet compete against immunogenic chemotherapy.

Patients And Methods: We analyzed by functional flow cytometry the immune dynamics of primary and metastatic axillary nodes (mLN) in early breast cancers after exposure to T cell bispecific antibodies (TCB) bridging CD3ε and HER2 or CEACAM5, before and after chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz112DOI Listing
March 2019
1 Read

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Ann Oncol 2019 Mar 28. Epub 2019 Mar 28.

Department of Medical Oncology, UZ Brussel, Belgium.

Background: PD-1 blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration of treatment has not been established.

Patients And Methods: This academic real-world cohort study investigated the outcome of 185 advanced melanoma patients who electively discontinued anti-PD-1 therapy with pembrolizumab (N = 167) or nivolumab (N = 18) in the absence of disease progression (PD) or treatment-limiting toxicity (TLT) at 14 medical centres across Europe and Australia.

Results: Median time on treatment was 12 months (range 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz110DOI Listing
March 2019
1 Read

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Ann Oncol 2019 Mar 27. Epub 2019 Mar 27.

Drug Development Unit Nashville, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.

Background: Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a PD-L1 inhibitor, atezolizumab, in patients with solid tumors.

Patients And Methods: This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz113DOI Listing
March 2019
1 Read

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.

Ann Oncol 2019 Mar 27. Epub 2019 Mar 27.

Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.

Background: Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications-including bleeding and potential drug-drug interactions with chemotherapy-associated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagulants (DOACs) could partially overcome these issues, but until recently there were no large clinical trials assessing their efficacy and safety in cancer patients.

Methods: This review summarizes clinical treatment guidelines, prior clinical and real-world evidence for anticoagulant choice, recent clinical trials assessing DOACs for cancer-associated VTE (ie, Hokusai-VTE Cancer, SELECT-D, CARAVAGGIO, and ADAM VTE), and special considerations for DOAC use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz111DOI Listing
March 2019
2 Reads

Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.

Ann Oncol 2019 Mar 27. Epub 2019 Mar 27.

Department of Liver Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

Background: Hepatocellular carcinoma (HCC) often presents with multiple nodules within the liver, with limited effective interventions. The high genetic heterogeneity of HCC might be the major cause of treatment failure. We aimed to characterize genomic heterogeneity, infer clonal evolution, investigate RNA expression pattern and explore tumour immune microenvironment profile of multifocal HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz103DOI Listing

Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma.

Ann Oncol 2019 Mar 26. Epub 2019 Mar 26.

Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

Background: Early-stage nasopharyngeal carcinoma (NPC) evades detection when the primary tumor is hidden from view on endoscopic examination. Therefore, in a prospective study of subjects being screened for NPC using plasma Epstein-Barr virus (EBV) DNA we conducted a study to investigate whether magnetic resonance imaging (MRI) could detect endoscopically occult NPC.

Patients And Methods: Participants with persistently positive EBV DNA underwent endoscopic examination and biopsy when suspicious for NPC, followed by MRI blinded to the endoscopic findings. Read More

View Article

Download full-text PDF

Source
http://fdslive.oup.com/www.oup.com/pdf/production_in_progres
Publisher Site
http://dx.doi.org/10.1093/annonc/mdz106DOI Listing
March 2019
2 Reads

How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.

Ann Oncol 2019 Mar 26. Epub 2019 Mar 26.

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, New York, NY, USA.

Antibodies that target programmed death 1 (PD-1) or its ligand (programmed death ligand 1 (PD-L1) have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy, in combination with chemotherapy, other immunotherapies, and anti-angiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz109DOI Listing
March 2019
1 Read

Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.

Ann Oncol 2019 Mar 26. Epub 2019 Mar 26.

Department of Neurology and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz114DOI Listing

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Ann Oncol 2019 Mar 23. Epub 2019 Mar 23.

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA.

Background: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation are key determinants of response to HER2-targeted treatments without chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz076DOI Listing
March 2019
2 Reads

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers.

Ann Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Introduction: Immunotherapy is regarded one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds - urging the quest for predictive biomarkers. We hypothesize that Artificial Intelligence (AI) algorithms can automatically quantify radiographic characteristics that are related to and may therefore act as non-invasive radiomic biomarkers for immunotherapy response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz108DOI Listing
March 2019
13 Reads

Revisiting surveillance schemes for cancer survivors.

Ann Oncol 2019 Mar 21. Epub 2019 Mar 21.

Institute of Health and Society, Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz107DOI Listing

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Ann Oncol 2019 Mar 20. Epub 2019 Mar 20.

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.

Background: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought to develop an ultra-deep plasma next-generation sequencing (NGS) assay for patients with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations in patients where tissue biopsy failed to identify an actionable alteration.

Patients And Methods: Plasma was prospectively collected from patients with advanced, progressive NSCLC. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/annonc/advance-article/doi/10.1093/
Publisher Site
http://dx.doi.org/10.1093/annonc/mdz046DOI Listing
March 2019
3 Reads

Enthuse for PERUSE: when clinical judgement overcomes regulatory boundaries.

Authors:
V Guarneri

Ann Oncol 2019 Mar 19. Epub 2019 Mar 19.

Department of Surgery, Oncology and Gastroenterology, University of Padova.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz091DOI Listing

NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis.

Ann Oncol 2019 Mar 18. Epub 2019 Mar 18.

State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, Xi'an, China.

Background: Somatic mutations of mitochondrial DNA (mtDNA) have been extensively identified mainly by traditional Sanger sequencing technology in various cancer types. However, low detection sensitivity of traditional methods greatly limits the comprehensive profiling of mtDNA somatic mutations in cancers, especially in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Moreover, the functional roles of mtDNA mutation in HBV-related hepatocarcinogenesis have not been systematically revealed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz105DOI Listing

European cancer mortality predictions for the year 2019 with focus on breast cancer.

Ann Oncol 2019 Mar 19. Epub 2019 Mar 19.

Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.

Background: To overcome the lag with which cancer statistics become available, we predicted numbers of deaths and rates from all cancers and selected cancer sites for 2019 in the European Union (EU).

Materials And Methods: We retrieved cancer death certifications and population data from the World Health Organization and Eurostat databases for 1970-2014. We obtained estimates for 2019 with a linear regression on number of deaths over the most recent trend period identified by a logarithmic Poisson joinpoint regression model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz051DOI Listing
March 2019
1 Read

Treatment of Patients with Recurrent Epithelial Ovarian Cancer for Whom Platinum is Still an Option.

Ann Oncol 2019 Mar 18. Epub 2019 Mar 18.

Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Section of Gynecologic Oncology; Oklahoma City, Oklahoma, USA.

Introduction: Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options.

Design: Authors performed review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz104DOI Listing
March 2019
2 Reads

Circulating driver gene mutations: what is the impact on melanoma patients' management?

Ann Oncol 2019 Mar 18. Epub 2019 Mar 18.

Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari; Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz090DOI Listing

Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.

Ann Oncol 2019 Mar 18. Epub 2019 Mar 18.

Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Introduction: Tumor mutation profiling is standard-of-care in lung carcinoma patients. However, comprehensive molecular profiling of small specimens, including core needle biopsy (CNB) and fine needle aspiration (FNA) specimens, may often be inadequate due to limited tissue. Centrifuged FNA supernatants, which are typically discarded, have emerged recently as a novel liquid-based biopsy for molecular testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz102DOI Listing
March 2019
2 Reads

Vitamin D: should public health recommendations also consider cancer outcomes?

Ann Oncol 2019 Mar 18. Epub 2019 Mar 18.

Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75 M.Asias Street, Goudi, GR-115 27, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz089DOI Listing

Molecular screening to select therapy for advanced cancer?

Ann Oncol 2019 Mar 13. Epub 2019 Mar 13.

126 boulevard Pereire, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz088DOI Listing

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

Ann Oncol 2019 Mar 13. Epub 2019 Mar 13.

Department of Medical Oncology & University Claude Bernard, Léon Bérard Cancer Center, Lyon, France.

Background: Antitumor activity of molecularly targeted agents (MTA) is guided by the presence of documented genomic alteration in specific histological subtypes. We aim to explore the feasibility, efficacy and therapeutic impact of molecular profiling in routine setting.

Patients And Methods: This multicentric prospective study enrolled adult or pediatric patients with solid or hematological advanced cancer previously treated in advanced/metastatic setting and non-eligible to curative treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz080DOI Listing
March 2019
1 Read

Divining Responder Populations from Survival Data.

Ann Oncol 2019 Mar 12. Epub 2019 Mar 12.

Department of Radiation Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Background: Biomarkers that predict treatment response are the foundation of precision medicine in clinical decision making and have the potential to significantly improve the efficiency of clinical trials. Such biomarkers may be identified prior to clinical testing but many trials enroll unselected populations. We hypothesized that time varying treatment effects in unselected trials may result from identifiable responder subpopulations that may have associated biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz087DOI Listing

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

Ann Oncol 2019 Mar 12. Epub 2019 Mar 12.

Faculty of Medicine and Health Sciences, Macquarie University, NSW, Australia.

Background: The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of disease relapse and mortality remains imprecise. With recent demonstrations of effective adjuvant targeted and immune checkpoint inhibitor therapy, more precise stratification of patients for costly and potentially toxic adjuvant therapy is needed. We report the utility of pre-operative circulating tumour DNA (ctDNA) in patients with high-risk stage III melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz075DOI Listing
March 2019
5 Reads

Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.

Ann Oncol 2019 Mar 12. Epub 2019 Mar 12.

Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.

Background: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression free survival (PFS) and early predictor of drug efficacy.

Patients And Methods: Patients with oestrogen receptor positive advanced metastatic breast cancer (ER+ mBC) in the BEECH study, paclitaxel plus placebo versus paclitaxel plus AKT inhibitor capivasertib, had plasma samples collected for ctDNA analysis at baseline and at multiple timepoints in the development cohort (safety run-in, part A) and validation cohort (randomised, part B). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz085DOI Listing

BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Ann Oncol 2019 Mar 12. Epub 2019 Mar 12.

Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Background: BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with first-line weekly paclitaxel for advanced or metastatic oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, and in a phosphoinositide 3-kinase, catalytic, alpha polypeptide mutation sub-population (PIK3CA+).

Patients And Methods: BEECH consisted of an open-label, phase 1b safety run-in (Part A) in 38 patients with advanced breast cancer, and a randomised, placebo-controlled, double-blind, phase 2 expansion (Part B) in 110 women with ER+/HER2- metastatic breast cancer. In Part A, patients received paclitaxel 90 mg/m2 (Days 1, 8 and 15 of a 28-day cycle) with capivasertib taken twice daily (BID) at two intermittent ascending dosing schedules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz086DOI Listing
March 2019
1 Read

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.

Ann Oncol 2019 Mar 9. Epub 2019 Mar 9.

Department of Oncology, Gustave Roussy, Villejuif, France.

Background: Few data are available on long-term fatigue (LTF) and quality-of-life (QoL) among epithelial ovarian cancer survivors (EOCS). In this case-control study, we compared LTF, symptoms and several QoL domains in EOCS relapse-free ≥3 years after first-line treatment and age-matched healthy women.

Patients And Methods: EOCS were recruited from 25 cooperative GINECO centers in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz074DOI Listing
March 2019
1 Read

Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Ann Oncol 2019 Mar 7. Epub 2019 Mar 7.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

Background: Concurrent PD-(L)1 plus osimertinib is associated with severe immune related adverse events (irAE) in EGFR mutant NSCLC. Now that PD-(L)1 inhibitors are routinely used as adjuvant and first-line treatments, sequential PD-(L)1 inhibition followed by osimertinib use may become more frequent and have unforeseen serious toxicity.

Methods: We identified patients with EGFR-mutant NSCLC who were treated with PD-(L)1 blockade and EGFR-TKIs, irrespective of drug or sequence of administration (total n = 126). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz077DOI Listing

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Ann Oncol 2019 Mar 6. Epub 2019 Mar 6.

Department of Medical Oncology, Hospital Universitario Reina Sofía, Córdoba, Spain. CIBERONC.

Background: Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend on certain sensitivity thresholds. We assessed whether ultra-selection of patients using a high-sensitive digital PCR (dPCR) to determine KRAS, NRAS, BRAF and PIK3CA status can improve clinical outcomes of panitumumab plus FOLFIRI.

Patients And Methods: This was a single-arm phase II trial that analysed 38 KRAS, NRAS, BRAF and PIK3CA hotspots in tumour tissues of irinotecan-resistant metastatic colorectal cancer patients who received panitumumab plus FOLFIRI until disease progression or early withdrawal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz082DOI Listing
March 2019
1 Read

Neuronal Autoantibodies Associated with Cognitive Impairment in Melanoma Patients.

Ann Oncol 2019 Mar 6. Epub 2019 Mar 6.

Department of Neurology, Charité - Universitätsmedizin Berlin, Germany.

Background: Cancer-related cognitive impairment is an important complication in cancer patients, yet the underlying mechanism remains unknown. Over the last decade, the field of paraneoplastic neurological syndromes has been dramatically changed by the discovery of new neuronal autoantibodies, some of them associated with cognitive impairment. We aimed to assess the prevalence of neuronal autoantibodies in melanoma patients and their association with neurological and cognitive dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz083DOI Listing
March 2019
2 Reads

Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden.

Ann Oncol 2019 Mar 6. Epub 2019 Mar 6.

Tisch Cancer Institute, Division of Hematology, Oncology, and Department of Medicine. Icahn School of Medicine at Mount Sinai.

Survival from head and neck cancers (HNCs) of the lip, oral cavity, pharynx, and larynx has increased by 10% over the past few decades. Little over half of patients who develop HNCs will survive beyond five years. Survival is lower for individuals in many countries where traditional risk factors such as tobacco smoking, alcohol drinking, and betel quid chewing are highly prevalent but tertiary healthcare center access is limited or unavailable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz084DOI Listing
March 2019
2 Reads

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Ann Oncol 2019 Feb 6. Epub 2019 Feb 6.

Peter MacCallum Cancer Centre, Melbourne, Australia.

Background: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma.

Patients And Methods: Somatic mutations were identified in 99/133 (74%) patients through tumor tissue sequencing. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/annonc/advance-article/doi/10.1093/
Publisher Site
http://dx.doi.org/10.1093/annonc/mdz048DOI Listing
February 2019
17 Reads

Chemotherapy-free treatments: are we ready for prime time?

Ann Oncol 2019 Mar 5. Epub 2019 Mar 5.

Clinica Universidad de Navarra, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz079DOI Listing

Communication training in oncology needs a theoretical framework.

Authors:
P Salander

Ann Oncol 2019 Mar 1. Epub 2019 Mar 1.

Pär Salander, Professor, Dept of Social Work, Umeå University, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz078DOI Listing

Targeting the MAPK Pathway in Advanced BRAF Wild-Type Melanoma.

Ann Oncol 2019 Mar 1. Epub 2019 Mar 1.

Dermatology and Translational Science, Department of Medicine, University of Pittsburgh Melanoma Program, University of Pittsburgh Cancer Institute, Pittsburgh, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz054DOI Listing

8O89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors.

Ann Oncol 2019 Feb;30(Supplement_1)

Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz029.001DOI Listing
February 2019

24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.

Ann Oncol 2019 Feb;30(Supplement_1)

Radiotherapy II, National Institute of Oncology Al. Treistioreanu, Bucharest, Romania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz029.017DOI Listing
February 2019

17PmicroRNA-16-5p enhances radiosensitivity through modulating cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells.

Authors:
L Gan F Wang

Ann Oncol 2019 Feb;30(Supplement_1)

Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz029.010DOI Listing
February 2019
1 Read

12PTargeting HIF1α/AP1 in hypoxia by novel 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides.

Ann Oncol 2019 Feb;30(Supplement_1)

Gause Institute of New Antibiotics, Moscow, Russian Federation.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz029.005DOI Listing
February 2019